News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Neuren Pharmaceuticals Limited Provides Clinical Trials Update
May 11, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Neuren Pharmaceuticals (ASX: NEU) today announced details on the status of its lead compounds, Glypromate® and NNZ-2566. Following is a summary of the current status of the trials. Neuren will provide further updates as the trials progress.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
Australia
MORE ON THIS TOPIC
ALS
Corcept Claims Survival Benefit in ALS Despite Missed Endpoint
June 6, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy
June 5, 2025
·
2 min read
·
Dan Samorodnitsky
IN PARTNERSHIP WITH IQVIA
AI’s Role in Decoding the FDA’s New Regulatory Communications
June 5, 2025
·
1 min read
·
Lori Ellis
Gene therapy
Sarepta Wins FDA’s Platform Technology Designation, Marking ‘Critical Shift’ in Gene Therapy Development
June 5, 2025
·
2 min read
·
Tristan Manalac
